Prevention of Secondary Infections by Interferon Gamma in ICU-acquired Sustained Immune-suppression

The goal of this clinical trial is to demonstrate the benefit of a standardized immunotherapy (Interferon gamma) on the incidence of secondary infections. . It will also learn about the safety of Interferon-gamma. The main questions it aims to answer are: Does Interferon-gamma: * reduces the Incidence of secondary infection episodes at three months * reduces the ICU mortality and at Day 90 * reduces the ICU and hospital length of stay * induces Biological immune restoration at Day 10 * has cost-consequence and cost-effectiveness Researchers will compare Interferon-gamma to a placebo (a look-alike substance that contains no drug) to see if Interferon-gamma works to treat sustained immunosuppression . Participants will: * Take Interferon-Gamma or a placebo for a maximum of 5 times between day 1 and day 9 * be monitored evety day until their ICU discharge and at day 30, 60 and 90

NCT Number	NCT06774235
Lead Sponsor	University Hospital, Limoges
Conditions	Sustained Immunosuppression
Enrollment	326 participants
Start Date	2025-07-09
Primary Completion	2028-10-09 (estimated)
Study Completion	2028-10-09 (estimated)
Updated on ClinicalTrials.gov	2025-11-20